Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Oncology
• Pharmacology
• Clinical Practice Guidelines

Background:

• Therapeutic recommendations for metastatic non-small cell lung cancer (NSCLC) are evolving rapidly.
• The NCCN Guidelines provide critical updates for clinicians managing advanced NSCLC.

Purpose of the Study:

• To summarize recent NCCN Guideline updates for targeted therapies and immunotherapies in metastatic NSCLC.
• To highlight key changes in treatment recommendations for advanced non-small cell lung cancer.

Main Methods:

• Review and synthesis of the NCCN Guidelines for Non-Small Cell Lung Cancer.
• Focus on updates related to targeted therapies and immunotherapies.
• Inclusion of specific drug recommendations from the 2017 updates.

Main Results:

• The 2017 NCCN Guidelines include new recommendations for atezolizumab, ceritinib, osimertinib, and pembrolizumab.
• These updates address the rapidly changing landscape of treatment for metastatic NSCLC.
• The guidelines focus on targeted agents and immunotherapies for advanced disease.

Conclusions:

• Clinicians should stay informed about the latest NCCN Guidelines for NSCLC management.
• Updated recommendations for targeted therapies and immunotherapies are crucial for optimizing patient outcomes in metastatic NSCLC.